CD38 and Miyoshi myopathy: Notably, the incorporation of targeted immunotherapies, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, has been one of the major breakthroughs in improving treatment response and clinical outcomes for both newly diagnosed (NDMM) and relapsed/refractory MM (RRMM) patients [1–9].